Strategic Growth SeQuent Scientific merged with Viyash Scientific, backed by Carlyle, creating a larger animal health platform. This indicates a broader customer base and expanded cross-selling opportunities across finished formulations, APIs, and analytical services.

Global Footprint Operating eight manufacturing facilities across Europe, Turkey, Brazil, and India with a USFDA approved veterinary API facility in Vizag highlights capability to supply multinational customers and support regional regulatory requirements, enabling partnerships with European and North American distributors.

Partnership Potential Strategic collaboration with Boehringer Ingelheim to sell companion animal products in India signals appetite for co-branding or exclusive distribution deals, suggesting reps should target OEMs and pharma majors for regional partnerships and private-label opportunities.

Financial Momentum Strong Q1 FY27 performance with double‑digit revenue growth and substantial EBITDA uplift indicates increasing buyer confidence and capacity for larger, multi-year supply agreements, especially in API and finished formulations for animal health.

Talent and Expansion Expansion of offices and ongoing hiring in QA and QC roles across India and Southern Asia points to scaling operations and quality assurance capabilities, presenting a chance to offer value-added services, compliance tooling, and training solutions to sustain growth.